D. Jackson (London, United Kingdom), I. Satia (Hamilton, Canada)
This session is built from abstracts published on the ERS Congress platform from 23 August, in an e-poster pdf format with a 3-minute audio narration. Participants and chairs of the session are invited to access all e-posters from 23 August to 4 September prior to the 1-hour live, online discussion scheduled from September 5-7. Please note that during live discussion there will be NO e-poster/abstract presentations, only discussion.
A stepped treatment algorithm for chronic respiratory disease using budesonide-formoterol in a rural healthcare setting in Vietnam
E. Huang (Sydney, Australia), G. Fox (Sydney, Australia), N. Pham (Hanoi, Vietnam), T. Nguyen (Hanoi, Vietnam), V. Vu (Hanoi, Vietnam), P. Thu (Hanoi, Vietnam), Q. Ngo (Hanoi, Vietnam), V. Nguyen (Hanoi, Vietnam), G. Marks (Hanoi, Vietnam)
|   |
Tezepelumab efficacy in patients with severe, uncontrolled asthma and comorbid nasal polyps in NAVIGATOR
A. Menzies-Gow (London, United Kingdom), J. Corren (Los Angeles, United States of America), E. Israel (Boston, United States of America), T. Welte (Hannover, Germany), C. Ambrose (Gaithersburg, United States of America), B. Cook (Gaithersburg, United States of America), G. Hunter (Cambridge, United Kingdom), J. Llanos-Ackert (Thousand Oaks, United States of America), G. Colice (Gaithersburg, United States of America)
| |
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma
I. Hoof (Hørsholm, Denmark), M. Witten (Hørsholm, Denmark), T. Stranzl (Hørsholm, Denmark), S. Brand (Hørsholm, Denmark), M. Shamji (London, United Kingdom), E. Bateman (Cape Town, South Africa), E. Bleecker (Tucson, United States of America), P. Andersen (Hørsholm, Denmark)
| |
Characteristics of super-responders to anti IL-5 biologics in a nationwide Danish severe asthma cohort
M. Baastrup Soendergaard (Copenhagen, Denmark), S. Hansen (Copenhagen, Denmark), O. Hilberg (Vejle, Denmark), C. Suppli Ulrik (Hvidovre, Denmark), K. Dahl Assing (Aalborg, Denmark), A. Wimmer-Aune (Aalborg, Denmark), A. Bjerrum (Århus, Denmark), L. Calderon Dongo (Roskilde, Denmark), M. Ghanizada (Copenhagen, Denmark), C. Wølhk (Copenhagen, Denmark), C. Porsbjerg (Copenhagen, Denmark)
| |
BIOLOGICS SWITCH IN SEVERE EOSINOPHILIC ASTHMA
M. Caminati (Verona (VR), Italy), G. Guarnieri (Padova , Italy), D. Bagnasco (Genova, Italy), F. Chieco Bianchi (Padova , Italy), E. Carpagnano (Foggia, Italy), M. Maule (Verona, Italy), B. Molena (Padova , Italy), G. Pelaia (Catanzaro, Italy), L. Pini (Brescia, Italy), G. Senna (Verona, Italy), A. Vianello (Verona, Italy), E. Crisafulli (Verona, Italy)
| |
Effect of dupilumab on improving physical activity in patients with severe asthma
L. Sher (Rolling Hills Estates, CA, United States of America), S. Quirce (Madrid, Spain), G. Passalacqua (Genoa, Italy), C. Taillé (Paris, France), L. Cohn (New Haven, CT, United States of America), N. Daizadeh (Cambridge, MA, United States of America), N. Pandit-Abid (Bridgewater, NJ, United States of America), B. Ortiz (Tarrytown, NY, United States of America), A. Khan (Chilly-Mazarin, France), Y. Zhang (Tarrytown, NY, United States of America)
| |
Staphylococcal Enterotoxins sensitization and response of Omalizumab in severe atopic and non atopic asthma
N. Migueres (Strasbourg, France), A. Poirot (Strasbourg, France), N. Zhang (Ghent, Belgium), C. Bachert (Ghent, Belgium), F. De Blay (Strasbourg, France)
| |
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
M. Farnik (Katowice, Poland), K. Zawada-Drozd (Katowice, Poland), A. Barczyk (Katowice, Poland)
| |
Clinically Meaningful Improvement in Total Rhinoconjunctivitis Score with Olopatadine/mometasone Combination Nasal Spray in Patients with Seasonal Allergic Rhinitis: A Pooled Analysis
E. Meltzer (San Diego, CA, United States of America), W. Wu (Watford, WD18 9YA, United Kingdom), A. Christensen (Melbourne, VIC, Australia), J. Wheeler (Melbourne, VIC, Australia), V. Aggarwal (Mumbai, India), C. Caracta (Mahwah, NJ, United States of America)
| |
Population pharmacokinetic and exposure-response analyses to support fixed dosing of tezepelumab in patients with severe asthma
Y. Zheng (South San Francisco, United States of America), Y. Guan (South San Francisco, United States of America), Y. Gao (Shanghai, China), L. Liu (Shanghai, China), L. Abuqayyas (Cambridge, United States of America), Å. Hellqvist (Gothenburg, Sweden), K. Bowen (Gaithersburg, United States of America), G. Colice (Gaithersburg, United States of America), A. Macdonald (Cambridge, United Kingdom)
| |
Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists
H. Reddel (Sydney, Australia), G. Brusselle (Ghent, Belgium), R. Lamarca (Barcelona, Spain), P. Gustafson (Gothenburg, Sweden), G. Anderson (Melbourne, Australia), C. Jorup (Gothenburg, Sweden)
| |
Long-Acting Beta Agonist Asthma Pharmacogenetic Loci Identified in Two Multi-Racial Asthma Clinical Trials
V. Ortega (Winston-Salem, NC, United States of America), M. Daya (Denver, CO, United States of America), E. Ampleford (Winston-Salem, NC, United States of America), G. Hawkins (Winston-Salem, NC, United States of America), W. Moore (Winston-Salem, NC, United States of America), S. Peters (Winston-Salem, NC, United States of America), K. Barnes (Denver, CO, United States of America), E. Bleecker (Tucson, AZ, United States of America), D. Meyers (Tucson, AZ, United States of America)
| |
“A RANDOMISED CONTROLLED STUDY ON EFFECT OF ORAL MAGNESIUM SUPPLEMENTS IN CONTROL OF SYMPTOMS OF BRONCHIAL ASTHMA AND LUNG FUNCTION PARAMETERS”
Y. ROWHIT (CHENNAI, India)
| |
Transitioning from hospital-based biologic care to home care in a severe asthma patient population; a patients’ perspective
R. Robinson (Liverpool, United Kingdom), K. Hunter (Liverpool, United Kingdom), D. Mclenaghan (Liverpool, United Kingdom), F. Shiham (Liverpool, United Kingdom), C. Lowe (Liverpool, United Kingdom), J. Byrne (Liverpool, United Kingdom), L. Chishimba (Liverpool, United Kingdom), S. Zaidi (Liverpool, United Kingdom), G. Jones (Liverpool, United Kingdom), H. Joplin (Liverpool, United Kingdom), H. Burhan (Liverpool, United Kingdom)
| |
Impact of mepolizumab in severe asthma with nasal polyps
E. M. Tinoco (Vila Nova de Gaia, Portugal), A. Gigante (Vila Nova de Gaia, Portugal), A. Fernandes (Matosinhos, Portugal), B. Cabrita (Matosinhos, Portugal), C. Santa (Vila Nova de Gaia, Portugal), I. Sucena (Vila Nova de Gaia, Portugal), S. Martins (Covilhã, Portugal), D. Machado (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal)
| |
Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
G. Van Hulst (Liège , Belgium), J. Jorssen (Liège, Belgium), N. Jacobs (Liège, Belgium), M. Henket (Liège, Belgium), R. Louis (Liège, Belgium), F. Schleich (Liège, Belgium), F. Bureau (Liège, Belgium), C. Desmet (Liège, Belgium)
| |
Late Breaking Abstract - Aldo-keto reductases expression correlate corticoids efficacy in vitro and on chronic rhinosinusitis with nasal polyps
A. Morell (Hradec Králové, Czech Republic), J. Milara (Valencia, Spain), L. Laštovicková (Hradec Králové, Czech Republic), I. Roger (Valencia, Spain), A. García-Lliberós (Valencia, Spain), E. Zapater-Latorre (Valencia, Spain), M. Armengot (Valencia, Spain), J. Cortijo (Valencia, Spain), V. Wsól (Hradec Králové, Czech Republic)
| |
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
S. Noorduyn (Mississauga, Canada), B. Lancaster (Mississauga, Canada), A. Gendron (Montreal, Canada), L. Mbuagbaw (Hamilton, Canada), E. Penz (Saskatoon, Canada)
| |
Late Breaking Abstract - Real-life rapidity of dupilumab effects on symptom control, lung function and prednisone intake in patients with severe eosinophilic asthma and nasal polyposis
C. Pelaia (Catanzaro (CZ), Italy), N. Lombardo (Catanzaro (CZ), Italy), M. Busceti (Catanzaro (CZ), Italy), A. Dragone (Catanzaro (CZ), Italy), G. Piazzetta (Catanzaro (CZ), Italy), C. Crimi (Catania (CT), Italy), A. Vatrella (Salerno (SA), Italy), G. Pelaia (Catanzaro (CZ), Italy)
| |
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
M. Przybyszowski (Kraków, Poland), I. Gross-Sondej (Kraków, Poland), J. Zarychta (Zakopane, Poland), S. Bazan-Socha (Kraków, Poland), G. Bochenek (Kraków, Poland), J. Soja (Kraków, Poland), K. Sladek (Kraków, Poland)
| |